Results 91 to 100 of about 3,116 (111)

Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma. [PDF]

Haematologica
Mateos MV, Weisel K, Terpos E, Delimpasi S, Kastritis E, Zamagni E, Delforge M, Ocio E, Katodritou E, Gay F, Larocca A, Leleu X, Otero PR, Schjesvold F, Cavo M, Dimopoulos MA.   +15 more
europepmc   +1 more source

[Association between environmental noise exposure and sleep quality in adults living in Medellín, Colombia, 2022: an exploratory study]. [PDF]

Cad Saude Publica
Rojas-Sánchez OA, Ochoa-Villegas J, Marín D, Piñeros-Jiménez JG, Rodriguez-Villamizar LA.   +4 more
europepmc   +1 more source

General health, anxiety, and depression: relationship with perceived self-efficacy and positive mental health in nursing students. [PDF]

Rev Esc Enferm USP
Bandeira EO, Pompeo DA, Sasaki NSGMDS, Pancote CG, Menezes-Júnior LAA, Alves DM, Eid LP, Lourenção LG.   +7 more
europepmc   +1 more source

Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D Ligands. [PDF]

Int J Mol Sci
Díaz-Tejedor A, Rodríguez-Ubreva J, Ciudad L, Lorenzo-Mohamed M, González-Rodríguez M, Castellanos B, Sotolongo-Ravelo J, San-Segundo L, Corchete LA, González-Méndez L, Martín-Sánchez M, Mateos MV, Ocio EM, Garayoa M, Paíno T.   +14 more
europepmc   +1 more source

Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma. [PDF]

Adv Ther
Einsele H, Moreau P, Bahlis N, Bhutani M, Vincent L, Karlin L, Perrot A, Goldschmidt H, van de Donk NWCJ, Ocio EM, Martinez-Lopez J, Rodríguez-Otero P, Dytfeld D, Diels J, Strulev V, Haddad I, Renaud T, Ammann E, Cabrieto J, Perualila N, Gan R, Zhang Y, Parekh T, Albrecht C, Weisel K, Mateos MV.   +25 more
europepmc   +1 more source

O TEATRO ANARQUISTA E O CONCEITO DE ARTE NA IMPRENSA OPERÁRIA DE 1901 A 1922

Projeto História, 2012
Eduardo Gramani Hipólide
doaj  

The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression. [PDF]

Blood Cancer J
Medina-Herrera A, Vazquez I, Cuenca I, Rosa-Rosa JM, Ariceta B, Jimenez C, Fernandez-Mercado M, Larrayoz MJ, Gutierrez NC, Fernandez-Guijarro M, Gonzalez-Calle V, Rodriguez-Otero P, Oriol A, Rosiñol L, Alegre A, Escalante F, De La Rubia J, Teruel AI, De Arriba F, Hernandez MT, Lopez-Jimenez J, Ocio EM, Puig N, Paiva B, Lahuerta JJ, Bladé J, San Miguel JF, Mateos MV, Martinez-Lopez J, Martinez-Lopez J, Calasanz MJ, Garcia-Sanz R, GEM/PETHEMA (Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group.   +32 more
europepmc   +1 more source